EP1185528A4 - Inhibiteurs de production de il-12 - Google Patents

Inhibiteurs de production de il-12

Info

Publication number
EP1185528A4
EP1185528A4 EP00941360A EP00941360A EP1185528A4 EP 1185528 A4 EP1185528 A4 EP 1185528A4 EP 00941360 A EP00941360 A EP 00941360A EP 00941360 A EP00941360 A EP 00941360A EP 1185528 A4 EP1185528 A4 EP 1185528A4
Authority
EP
European Patent Office
Prior art keywords
compound
heteroaryl
aryl
alkyl
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00941360A
Other languages
German (de)
English (en)
Other versions
EP1185528A1 (fr
Inventor
Mitsunori Ono
Yumiko Wada
Beatrice Brunkhorst
Tadeusz Warchol
Wojciech Wrona
Dan Zhou
Nha Huu Vo
Stephen Gillies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SBR Pharmaceuticals Inc
Original Assignee
SBR Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SBR Pharmaceuticals Inc filed Critical SBR Pharmaceuticals Inc
Publication of EP1185528A1 publication Critical patent/EP1185528A1/fr
Publication of EP1185528A4 publication Critical patent/EP1185528A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • Cytokines such as interleukin-12 (IL-12) mediate the acute phase response to inflammatory stimuli, enhance the microbicidal functions of macrophages and other cells, and promote specific lymphocyte responses. See, e.g., I Q Fearon and Locksley, Science 272:50 (1996).
  • IL-12 interleukin-12
  • L 1 is -A 1 -B 1 -, in which -A 1 - is -(CH(R a )) -, -0-, -S-, or -N(R b )- and -B 1 - is -(CH(R C )) - or a bond.
  • Each of R a and R c is hydrogen, 5 alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl , formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkylcarbonyloxy, cycloalkyl, heterocycloalkyl, aryl, 0 aralkyl, heteroaryl, or heteroaralkyl.
  • R b is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl. Each of m and n, independently, is 1-8.
  • W is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which « being optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, or 0 alkylcarbonyloxy.
  • R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 1S , R 16 , R 17 , R 18 , R 19 , R 2 °, R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , and R 27 independently, is hydrogen, alkyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl.
  • Y is -R'-L'-R" wherein R' is a bond, or cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, each of which optionally being substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkylcarbonyloxy, or alkoxycarbonylimino.
  • L' is a bond, -0-, -S-, -N(R 28 )-, -N(R 29 )-CO-, -CO-N(R 30 )-, -CO-0-, or -O- CO- .
  • R 28 , R 29 , and R 30 independently, is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl.
  • R" is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, each of which being optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, or alkylcarbonyloxy.
  • Z is morpholinyl which is optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, or alkylcarbonyloxy.
  • Another aspect of this invention relates to a method of inhibiting IL-12 production, which includes administering to a patient in need thereof an effective amount of a compound of formula (I) , supra - X is triazinyl.
  • L 1 is -A ⁇ -B 1 - , in which -A 1 - is -(CH(R a )) m -, -0-, -S-, or -N(R b )- and -B 1 - is -(CH(R c )) n - or a bond.
  • Each of R a and R c is hydrogen, alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkylcarbonyloxy, cycloalkyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl.
  • R b is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl. Each of m and n, independently, is 1-8.
  • W is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl, each of which being optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, or alkylcarbonyloxy.
  • L 2 is -A 2 -B 2
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R" , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , and R 27 independently, is hydrogen, alkyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl.
  • Y is -R'-L'-R" wherein R' is a bond, or cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkylcarbonyloxy, or alkoxycarbonylimino.
  • L' is a bond, -0-, -S-, -N(R 28 )-, -N(R 29 )-C0-, -CO-N(R 30 ) -, -CO-0-, or -O-CO- .
  • R 28 , R 29 , and R 30 independently, is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl.
  • R" is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, each of which optionally being substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, or alkylcarbonyloxy.
  • Z is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which being optionally substituted with alkyl, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, halo, haloalkyl, amino, aminoalkyl, thio, thioalkyl, cyano, nitro, alkylcarbonylamino, alkylaminocarbonyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, or alkylcarbonyloxy.
  • a pharmaceutically acceptable salt of a compound of formula (I) is also within the scope of this invention.
  • a salt can be formed between a negatively charged substituent such as carboxylate and a positively charged counte ⁇ on such as an alkali metal ion (e.g., a sodium ion or a potassium ion) ; an alkaline earth metal ion (e.g., a magnesium ion or a calcium ion); an ammonium ion (NH + ) ; or an organic ammonium group such as tetramethylammonium ion or dnsopropylethyl -ammonium ion.
  • a negatively charged substituent such as carboxylate
  • a positively charged counte ⁇ on such as an alkali metal ion (e.g., a sodium ion or a potassium ion) ; an alkaline earth metal ion (e.g., a magnesium ion or a calcium ion); an am
  • an ammo substituent can form a salt with a negatively charged counterion.
  • Suitable counterions include, but are not limited to, chloride, hydrochlo ⁇ de, bromide, iodide, sulfate, nitrate, phosphate, or acetate.
  • alkyl is a straight or branched hydrocarbon chain containing 1 to 12 carbon atoms.
  • alkyl examples include, but are not limited to, methyl, ethyl, propyl , isopropyl, butyl, isobutyl, sec- butyl, tert-butyl, n-pentyl, 2-methylhexyl , 3-ethyloctyl , a n 4-ethyldecyl .
  • alkenyl refers to a straight or branched hydrocarbon chain containing 2 to 12 carbon atoms and one or more (e.g., 1-6) double bonds.
  • alkynyl also refers to such a hydrocarbon chain, except that the chain contains one or more triple bonds instead of double bonds.
  • Some examples of alkenyl and alkynyl are allyl, 2-butenyl, 2-pentenyl, 2-hexenyl, 2-butynyl, 2-pentynyl and 2-hexynyl.
  • cycloalkyl is meant a cyclic alkyl group containing 3 to 8 carbon atoms. Some examples of cycloalkyl are cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl , and norbornyl .
  • Heterocycloalkyl is a cycloalkyl group containing 1-3 heteroatoms such as nitrogen, oxygen, or sulfur. Examples of heterocycloalkyl include piperidinyl, piperazinyl, tetrahydropyranyl , tetrahydrofuryl , and morpholinyl.
  • Cycloalkenyl is a cycloalkyl group containing one or more (e.g., 1-3) double bonds. Examples of such a group include cyclopentenyl , 1, 4-cyclohexadienyl , cycloheptenyl , and cyclooctenyl groups.
  • heterocycloalkenyl is a heterocycloalkyl group containing one or more double bonds.
  • aryl is an aromatic group containing 6-12 ring atoms and can contain fused rings, which may be saturated, unsaturated, or aromatic. Examples of an aryl group include phenyl, naphthyl, biphenyl, phenanthryl , and anthracyl .
  • Heteroaryl is aryl containing 1-3 heteroatoms such as nitrogen, oxygen, or sulfur and can contain fused rings .
  • Some examples of heteroaryl are pyridyl, furanyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, imidazolyl, indolyl , benzofuranyl , and benzthiazolyl .
  • a cyclic moiety can be cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, or heteroaryl.
  • a tricyclic moiety is a fused ring formed from three of the just-mentioned moieties.
  • An example of a tricyclic moiety is dibenzocycloheptenyl .
  • Heteroatoms such as nitrogen, oxygen, and sulfur can be included in the cyclic moiety.
  • An amino group can be unsubstituted, mono- substituted, or di-substituted. It can be substituted with groups such as alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl.
  • Halo refers to fluoro, chloro, bromo, or iodo.
  • a compound of formula (I) can be prepared in a stepwise manner by using cyanuric chloride as a starting material.
  • Cyanuric chloride is commercially available.
  • the three chloro groups of cyanuric chloride can be successively displaced by various nucleophilic substituents. The order of displacement is not of particular importance.
  • a chloro group of cyanuric chloride can be substituted with a nucleophile W-B 1 - ⁇ 1 -U wherein A 1 is -0-,
  • R a and m have been defined above
  • organometallic compound of group IA or IIA metal e.g., a Grignard reagent.
  • the organometallic compound acts as a nucleophile and reacts with a compound with a good leaving group, e.g., an alkyl halide, to form a carbon- carbon linkage.
  • a chloro group of cyanuric chloride can also be displaced by a nucleophile ZH (Z has been defined above) , e.g., morpholine, to form a morpholinyl triazine compound as shown in the following reaction (see, e.g., Step (2) of Example 1 for details) :
  • a chloro group of cyanuric chloride can undergo yet another displacement reaction with a nucleophile H-A 2 -B 2 -Y wherein A 2 is an amine and B 2 is a bond to form an amino linkage between the triazine ring and the nucleophile.
  • Some examples of such an amine include 3-aminocarbazole, 6-aminobenzofuran, and 4- (3-methylphenyl) aniline . See, e.g., Step (3) of Example 5.
  • Step (3) of Example 5 See, e.g., Step (3) of Example 5.
  • the chloro group can be first displaced by hydrazine, and the primary amine of the coupled hydrazine moiety can then react with an aldehyde to form an imine linkage :
  • a compound of formula (I) wherein the linkage -A-B 2 - is a carbon-carbon linkage can be formed, e.g., via an organometallic intermediate described above and further reacting such an intermediate with a nucleophile.
  • linkages can be prepared by similar nucleophilic reactions. Sensitive moieties on both the triazinyl intermediates and the nucleophiles can be protected prior to coupling. For suitable protecting groups, see, e.g., Greene, T. . , Protective Groups in Organic Synthesis, John Wiley & Sons, Inc., New York (1981) .
  • a compound of formula (I) prepared by the methods shown above can be purified by flash column chromatography, preparative high performance liquid chromatography, or crystallization.
  • a pharmaceutical composition containing an effective amount of one or more compounds of this invention for inhibiting IL-12 production or treating an IL-12 mediated disorders is also within the scope of this invention.
  • Some examples of IL-12 mediated disorders include sepsis and autoimmune disorders, e.g., rheumatoid arthritis, Crohn's disease, psorasis, and multiple sclerosis.
  • the use of a compound of this invention or a salt thereof for the manufacture of a medicament for inhibiting IL-12 production or treating the above-mentioned IL-12-mediated disorders is also within the scope of this invention.
  • Still another aspect of this invention is a method of treating an IL-12 -mediated disorder, e.g., sepsis, by administering to a patient a pharmaceutical composition containing an effective amount of a compound of this invention or a salt thereof.
  • An effective amount is defined as the amount which is required to confer a therapeutic effect on the treated patient, and is typically determined based on age, surface area, weight, and condition of the patient. The interrelationship of dosages for animals and humans (based on milligrams per meter squared of body surface) is described by Freireich et al . , Cancer Chemother. Rep. 1966, 50, 219. Body surface area may be approximately determined from height and weight of the patient.
  • an effective amount of a compound of this invention can range from about 0.1 mg/kg to about 100 mg/kg. Effective doses will also vary, as recognized by those skilled in the art, dependant on route of administration, excipient usage, and the possibility of co-usage with other therapeutic treatments such as the use of other anti- inflammatory agents.
  • the pharmaceutical composition may be administered via the parenteral route, including orally, topically, subcutaneously, intraperitoneally, intramuscularly, and intravenously.
  • parenteral dosage forms include aqueous solutions, isotonic saline or 5% glucose of the active agent, or other well-known pharmaceutically acceptable excipient.
  • Solubilizing agents such as cyclodextrins, or other solubilizing agents well-known to those familiar with the art, can be utilized as pharmaceutical excipients for delivery of the therapeutic compounds .
  • compound of this invention can be formulated into dosage forms for other routes of administration utilizing conventional methods. For example, it can be formulated in a capsule, a gel seal, or a tablet for oral administration.
  • Capsules may contain any standard pharmaceutically acceptable materials such as gelatin or cellulose. Tablets may be formulated in accordance with conventional procedures by compressing mixtures of a compound of this invention with a solid carrier and a lubricant. Examples of solid carriers include starch and sugar bentonite. A compound of this invention can also be administered in a form of a hard shell tablet or a capsule containing a binder, e.g., lactose or mannitol, a conventional filler, and a tableting agent.
  • a binder e.g., lactose or mannitol
  • the biological activities of a compound of this invention can be evaluated by a number of cell -based assays.
  • One of such assays can be conducted using mononuclear cells from human peripheral blood (PBMC) .
  • Human Interferon gamma (IFN- ⁇ ) and lipopolysaccharide are added to the cell-containing solutions to induce IL-12 production.
  • a solution containing a compound of this invention is added to each well.
  • the level of inhibition of IL-12 production can be measured by determining the amount of P70 (i.e., IL-12) by using a sandwich ELISA assay - 1 with anti-human IL-12 antibodies. ICso of each test compound can then be determined and potent compounds are selected for further testing.
  • the selected compounds can be further assayed in parallel on two types of cells, PBMC and human leukemia mononuclear cell line (THP-1) , for verification. More specifically, each test compound is added to a well of stimulated PBMC or THF-1 cells. PBMC are stimulated by a combination of IFN- ⁇ and LPS, and THP-1 cells are stimulated by a combination of IFN- ⁇ and pansorbin. The amount of P70 present in each well is then measured using a sandwich ELISA with anti -human IL-12 antibodies and IC is determined for each test compound.
  • THP-1 human leukemia mononuclear cell line
  • the cytotoxity of the test compounds of this invention can be determined by using a bioreductive assay. Specifically, PBMC and THP-1 cells are incubated with the test compounds. Viability are evaluated by the ability of mitochondrial dehydrogenases of the incubated cells to reduce 3- (4, 5-dimethylthiazole-2-yl) -5- (3- carboxymethoxy-phenyl) -2- (4-sulfophenyl) -2H-tetrazolium (MTS) in the presence of phenazine methosulfate (PMS) .
  • PBMC and THP-1 cells are incubated with the test compounds. Viability are evaluated by the ability of mitochondrial dehydrogenases of the incubated cells to reduce 3- (4, 5-dimethylthiazole-2-yl) -5- (3- carboxymethoxy-phenyl) -2- (4-sulfophenyl) -2H-tetrazolium (MTS) in the presence of phenazine
  • Compounds of this invention can also be evaluated by animal studies.
  • One of such studies involves the ability of a test compound to inhibit septic shock. Animals are injected with LPS to induce septic shock. Mortality rate of the induced animals is monitored after administering to the animals a test compound and compared with that of a control experiment in which the induced animals are not treated.
  • the following specific examples, which describe syntheses and biological testings of compounds of this invention, are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
  • X H nuclear magnetic resonance spectra were recorded on a Varian Mercury 300 MHz spectrometer.
  • ES mass spectra were recorded on a Finnigan Navigator mass spectrometer.
  • Step (1)
  • Cyanuric chloride (18.7 g, 0.10 mol) was added to a solution of methylene chloride (100 mL) . Phenethyl alcohol (12.2 g, 0.10 mol) and N, N-dimethyacetamide (26.1 g, 0.30 mol) were then added after cyanuric chloride was dissolved. The reaction mixture was refluxed for 10 hours, cooled to room temperature, diluted with methylene chloride (100 ml), washed with water (100 ml, 3 times), dried over MgSO , and then filtered.
  • Step (2) Morpholine (8.70 g, 0.10 mol) and diisopropylethylamine (12.9 g, 0.10 mol) were dissolved in 20 ml methylene chloride and added dropwise into the filtrate from step (1) at 0°C. The reaction was monitored by TLC (EtOAc :Hexane, 1:4). After the product was formed, the reaction mixture was washed with IN HCI (50 ml, 3 times), saturated NaHCO. (50 ml), brine (50 ml), then dried over MgSO . The solvent was removed under reduced pressure. The crude residue was recrystallized from acetone/water solution to give 20.5 g of the desired triazine monochloride intermediate. Step (3)
  • the triazine monochloride intermediate (20.0 g, j 0 0.062 mol) was dissolved in 100 ml ethanol and added dropwise to a solution of hydrazine monohydrate (25.0 g, 0.62 mol) in ethanol (50 ml) . The mixture was stirred at room temperature for 30 minutes before 20 ml water was added. Excess ethanol was then removed under reduced j pressure and the desired triazinyl hydrazine precipitated out which was collected by filtration and washed with water.
  • Triazinyl hydrazine (316 mg, 1.0 mmol) and indole 3- carboxylaldehyde (145 mg, 1.0 mmol) were added to 5 ml 0 methanol and warmed to form a homogeneous solution. Two drops of glacial acetic acid was then added. After the reaction mixture was allowed to stand at room temperature for 10 hours, the product precipitated which was then filtered, washed with methanol, and dried under reduced 5 pressure to yield compound 1 (395 mg, 89%) . ⁇ NMR
  • Step (3) Preparation of compound 2 Steps (1) and (2) of the preparation were prepared in an identical manner described in Example 1 except that 2- (4-methoxyphenyl) ethanol was used instead of phenethyl alcohol . 5 Step (3) :
  • Triazinyl monochloride (330 mg, 1.0 mmol) was added to 10 ml of 1,4 -dioxane, followed by the addition of 3- aminocarbazole (182 mg, 1.0 mmol) and diisopropylethylamine (129 mg, 1.0 mmol) .
  • 3- aminocarbazole 182 mg, 1.0 mmol
  • diisopropylethylamine 129 mg, 1.0 mmol
  • the triazine dichloride intermediate (3.0 g, 10 5 mmol) was dissolved m acetone (30 ml) After the acetone solution was cooled to 0°C, a 10 ml aqueous solution of sodium bicarbonate (0.842 g, 10 mmol) was added to the acetone solution with stirring. Morpholine (0.87 ml, 10 mmol) was added dropwise to mixture and j 0 white precipitate was formed within 10 minutes The precipitate was filtered and washed with water (3 times) and dried under vacuum to yield the desired triazine monochloride intermediate (4.0 g, >98%) as a white solid. Step (3) : j 5 The triazine monochloride intermediate (3.5 g,
  • Step (1)
  • Cyanuric chloride (13.66 g, 74 mmol) was dissolved j 0 in methylene chloride (100 ml) at -78°C, followed by the addition of diisopropylethylamine (12.9 ml, 74 mmol).
  • the reaction mixture was stirred for 5 minutes.
  • Step (2)
  • Step (3)
  • Steps (1) and (2) of the preparation were prepared in an identical manner described in Example 3 except that (3 , 4-dimethoxyphenyl) ethanol was used instead of 4- hydroxy-3-methoxyphenethyl alcohol .
  • Step (3)
  • the triazine monochloride intermediate (760 mg, 2.0 mmol) was dissolved in 10 ml DMF.
  • 4-(N-(2- methoxyphenyl) amino) aniline (429 mg, 2.0 mmol) and DIEA (387 mg, 3.0 mmol) were then added to the DMF solution.
  • the reaction mixture was allowed to react at 100°C for 15 hours. After cooling to room temperature, the mixture was diluted with ethyl acetate (50 ml), washed with HO (3 X 25 ml) , brine (25 ml) , dried over MgSO , filtered, and concentrated under reduced pressure.
  • Steps (1) and (2) of the preparation were identical to the corresponding steps described in Example 5.
  • Step (3) Steps (1) and (2) of the preparation were identical to the corresponding steps described in Example 5.
  • PBMC peripheral blood
  • fetal calf serum (10%)
  • penicillin penicillin
  • streptomycin L-glutamate
  • Human Interferon gamma IFN- ⁇ was added to the solution containing the cells at the concentration of 60 units/ml (obtained from Boehringer Mannheim; catalog no. 1040596) .
  • Example 29 The specificity of the nine selected compound (see Example 29) was tested on PBMC and human leukemia mononuclear cell line THP-1 in parallel to verify results .
  • PBMC peripheral blood mononuclear cells
  • IFN- ⁇ 200 U/mL
  • LPS 1 ⁇ g/mL
  • THP-1 cells were plated in wells of a 96-well plate at a concentration of 800,000 cells per well (100 ⁇ l). Human IFN- ⁇ was added at 2000 U/ml . The plate was incubated overnight under a 7% CO atmosphere at 37°C.
  • Each selected test compound (in 4X RPMI solution) was then added to a well of the 96 well plate with a final concentration of 1 ⁇ g/ml, which was then followed by the addition of Staph Aureus Cowan I (SAC or Pansorbin; obtained from Calbiochem; Lot # B15921) with a final concentration of 0.05%.
  • the plate was then gently vortexed and incubated for 16 hours under a 7% CO 2 atmosphere at 37°C.
  • Supernatant was harvested and was assayed for the amount of P70 present by using a sandwich ELISA with anti -human IL-12 antibodies (obtained from R&D systems; catalog no. mAb 611 and catalog no. BAF219) .
  • the nine selected test compounds all showed similar biological activities towards both PBMC and THP-1 cells.
  • THP-1 cell line The two most potent compounds showed a 10-fold increase in inhibiting IL-12 production over a known anti-inflammatory compound, dexamethazone .
  • the nine selected compounds were also assayed for cytotoxicity using a Cell Titer 96 Aqueous Non-radioactive kit (obtained from Promega, order 5 no. G5421) .
  • 3- (4, 5-Dimethylthiazole-2-yl) -5- (3- j 0 carboxymethoxy-phenyl) -2- (4-sulfophenyl) -2H-tetrazolium (MTS) was then added.
  • the nine test compounds all showed similar trend in cytotoxity toward the two cell lines.
  • the PBMC cell line one compound showed a CC of under 1 ⁇ M; five compounds showed a CC of between 2-10 ⁇ M; and three 5 compounds showed a CC so of 20 ⁇ M or above.
  • the THP-1 cell line one compound showed a CC of about 2 ⁇ M; five compounds showed a CC of about 20 ⁇ M; and three compounds showed a CC of above 20 ⁇ M.
  • four compounds 0 showed a lower cytotoxity toward the PBMC cell line, and three compounds showed a lower cytotoxity toward the THP- 1 cell line.
  • mice Three compounds of this invention were tested an animal study using Balb/c mice.
  • the mice were divided into groups of five. Septic shock was induced m each of them by single tradermal injection of LPS (1 ⁇ g/mL) m the foot pad. After 24 hours, a group of mice received (1) no treatment; another group received (2) vehicle only (10% DMSO and 18% Cremophor RH40) ; or three groups received (3) test compounds. More specifically, each group received a different test compound at a dosage of 10-20 mg/kg. The mice were dosed daily for three days and the mortality rate m each group was then recorded. The mice all died m the groups that received no treatment or vehicle only. Among the groups that received test compounds, two had a survival rate of 60% and 80%.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne un composé représenté par la formule (I), pouvant inhiber la production de IL-12. L'invention concerne également une méthode d'inhibition de la production de IL-12, consistant à administrer à un patient en ayant besoin une quantité efficace d'un composé représenté par la formule (I).
EP00941360A 1999-06-17 2000-06-12 Inhibiteurs de production de il-12 Withdrawn EP1185528A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13962399P 1999-06-17 1999-06-17
US139623P 1999-06-17
PCT/US2000/016094 WO2000078757A1 (fr) 1999-06-17 2000-06-12 Inhibiteurs de production de il-12

Publications (2)

Publication Number Publication Date
EP1185528A1 EP1185528A1 (fr) 2002-03-13
EP1185528A4 true EP1185528A4 (fr) 2003-03-26

Family

ID=22487544

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00941360A Withdrawn EP1185528A4 (fr) 1999-06-17 2000-06-12 Inhibiteurs de production de il-12

Country Status (5)

Country Link
EP (1) EP1185528A4 (fr)
JP (1) JP2003502424A (fr)
AU (1) AU781849C (fr)
TW (1) TWI265929B (fr)
WO (1) WO2000078757A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP4105949B2 (ja) 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
PT1355905E (pt) * 2000-12-21 2007-05-31 Vertex Pharma Compostos de pirazole úteis como inibidores de proteínaquinase
US6462078B1 (en) * 2001-01-29 2002-10-08 Shionogi Bioresearch Corp. Epoxyvibsanin B
EA200500299A1 (ru) 2002-08-02 2005-08-25 Вертекс Фармасьютикалз Инкорпорейтед Пиразольные композиции, используемые в качестве ингибиторов gsk-3
AU2003284142A1 (en) * 2002-10-15 2004-05-04 Synta Pharmaceuticals Corp Aromatic bicyclic heterocyles to modulate 1L-12 production
WO2005000404A2 (fr) * 2003-05-29 2005-01-06 Synta Pharmaceuticals, Corp. Composes heterocycliques permettant de prevenir et de traiter des troubles associes a une perte osseuse excessive
AU2004289304A1 (en) * 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Pyridine compounds
TWI344364B (en) 2003-11-10 2011-07-01 Synta Pharmaceuticals Corp Fused heterocyclic compounds
TWI359017B (en) * 2003-11-10 2012-03-01 Synta Pharmaceuticals Corp Heteroaryl-hydrazone compounds
EP1737845A4 (fr) * 2004-04-13 2010-07-21 Synta Pharmaceuticals Corp Inhibiteurs disel de production d'il-12
AU2005262322B2 (en) * 2004-07-01 2012-07-26 Synta Pharmaceuticals Corp. 2-substituted heteroaryl compounds
US7923557B2 (en) 2004-11-10 2011-04-12 Synta Pharmaceuticals Corporation Process for preparing trisubstituted pyrimidine compounds
WO2006053109A1 (fr) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Composes heteroaryle
EP1819341A4 (fr) * 2004-11-10 2011-06-29 Synta Pharmaceuticals Corp Composes modulateurs de la il-12
US7851466B2 (en) 2004-11-19 2010-12-14 Synta Pharmaceuticals Corp. Pyrimidine compounds and uses thereof
EP2176261B1 (fr) 2007-07-31 2012-12-19 Vertex Pharmaceuticals Incorporated Procédé de préparation de la 5-fluoro-1h-pyrazolo [3,4-b] pyridin-3-amine et des dérivés de celle-ci
ES2403040T3 (es) 2007-10-09 2013-05-13 Dow Agrosciences Llc (1,3,5)-triazinil-fenil-hidrazonas insecticidas
PT2262778T (pt) 2008-03-07 2019-11-19 Acraf Derivados de 1-benzil-3-hidroximetilindazolo e utilização dos mesmos no tratamento de doenças baseadas na expressão de mcp-1, cxcr1 e p40
PL2254870T3 (pl) 2008-03-07 2016-07-29 Acraf Pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób opartych na ekspresji MCP-1, CX3CR1
EP2440051A4 (fr) * 2009-06-08 2012-12-19 California Capital Equity Llc Dérivés de triazine et leurs applications thérapeutiques
CN102573480B (zh) * 2009-06-09 2015-06-10 加利福尼亚资本权益有限责任公司 三嗪衍生物及其治疗应用
CN102573482A (zh) * 2009-06-09 2012-07-11 加利福尼亚资本权益有限责任公司 苯乙烯基-三嗪衍生物及其治疗应用
CN106035343B (zh) 2010-07-20 2019-07-02 韦斯塔隆公司 三嗪类和嘧啶类杀虫剂
WO2019164861A1 (fr) 2018-02-21 2019-08-29 AI Therapeutics, Inc. Polythérapie avec apilimod et agents glutamatergiques

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0356412A1 (fr) * 1988-08-16 1990-02-28 U C B, S.A. Utilisation de 2-amino-4-morpholino-6-propyl-1,3,5-triazines pour la préparation de médicaments destinés au traitement des troubles de la cognition et de l'humeur.
EP0527117A1 (fr) * 1991-07-25 1993-02-10 U C B, S.A. Cyclopropylamino-1,3,5-triazines substituées
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
WO1999032121A1 (fr) * 1997-12-19 1999-07-01 Smithkline Beecham Corporation .0mposes d'imidazole heteroaryle substitues, leurs compositions et usages pharmaceutiques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1231369B (de) * 1964-03-05 1966-12-29 Basf Ag Verfahren zur Herstellung von Anthrachinon-farbstoffen

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0356412A1 (fr) * 1988-08-16 1990-02-28 U C B, S.A. Utilisation de 2-amino-4-morpholino-6-propyl-1,3,5-triazines pour la préparation de médicaments destinés au traitement des troubles de la cognition et de l'humeur.
EP0527117A1 (fr) * 1991-07-25 1993-02-10 U C B, S.A. Cyclopropylamino-1,3,5-triazines substituées
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5663334A (en) * 1993-07-16 1997-09-02 Smithkline Beecham Corporation Process for preparing pyrimidyl imidazoles
WO1999032121A1 (fr) * 1997-12-19 1999-07-01 Smithkline Beecham Corporation .0mposes d'imidazole heteroaryle substitues, leurs compositions et usages pharmaceutiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0078757A1 *

Also Published As

Publication number Publication date
TWI265929B (en) 2006-11-11
WO2000078757A1 (fr) 2000-12-28
AU5607400A (en) 2001-01-09
AU781849B2 (en) 2005-06-16
EP1185528A1 (fr) 2002-03-13
AU781849C (en) 2006-03-02
JP2003502424A (ja) 2003-01-21

Similar Documents

Publication Publication Date Title
AU781849C (en) Inhibitors of IL-12 production
US6384032B1 (en) Inhibitors of IL-12 production
AU2016317521B2 (en) Novel pyrazolo[3,4-d]pyrimidine compound or salt thereof
ES2244733T3 (es) Derivados de n-adamantilalquil-benzamida como antagonistas del receptor p2x7.
EP0747368B1 (fr) Dérivés de polyamines monocycliques, leur préparation et leur application comme agents antiviraux
ES2358988T3 (es) Benzamida y heteroarilamida como antagonistas del receptor p2x7.
CA2575232C (fr) 5-subsitue-2-phenylamine benzamide agissant en tant qu'inhibiteur mek
ES2286634T3 (es) Compuestos de azaindol como inhibidores de quinasas.
KR20050098848A (ko) 염증성 질환의 치료를 위한 ｐ2ｘ7-억제제로서의3-(3,5-디옥소-4,5-디히드로-3ｈ-(1,2,4)트리아진-2-일)-벤즈아미드 유도체
EP2281818A1 (fr) Composés condensés dérivés de la pyridazine et médicaments contenant lesdits composés comme ingrédients actifs
JPH07504654A (ja) オキソ及びヒドロキシ置換炭化水素のアミン誘導体
EP3004059B1 (fr) Dihydropyridinone utilisée en tant qu'inhibiteur de mgat2
ES2578290T3 (es) Derivados de oxazolina e isoxazolina como moduladores de CRAC
EP1741714A1 (fr) Composé hétérocylique et agent de tumeur anti-maligne contenant celui-ci comme ingrédient actif
KR20170033339A (ko) 새로운 인돌리진 유도체 및 신경변성 질환에서의 이들의 용도
CA3081564A1 (fr) Inhibiteur de protease a deux tetes
JP2018538355A (ja) ベンズアミド誘導体
WO2019235553A1 (fr) Dérivé d'azétidine, et promédicament de celui-ci
JPH03163074A (ja) フラン誘導体
EP0353474B1 (fr) Dérivé de glycérol et son utilisation pharmaceutique
TW442451B (en) Novel substituted alkyldiamine derivatives
WO1998058930A1 (fr) Composes de triazolo-1,4-diazepine et composition medicinale les contenant
EP2844643B1 (fr) Inhibiteurs pyrimidinedione carboxamide de la lipase endothéliale
US6344456B1 (en) Piperazinone derivatives and their uses
CA3151407A1 (fr) Composes d'indole carboxamide et leur utilisation pour le traitement d'infections mycobacteriennes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB IT

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GILLIES, STEPHEN

Inventor name: VO, NHA HUU

Inventor name: ZHOU, DAN

Inventor name: WRONA, WOJCIECH

Inventor name: WARCHOL, TADEUSZ

Inventor name: BRUNKHORST, BEATRICE

Inventor name: WADA, YUMIKO

Inventor name: ONO, MITSUNORI

A4 Supplementary search report drawn up and despatched

Effective date: 20030206

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 29/00 B

Ipc: 7A 61K 31/5375 B

Ipc: 7C 07D 413/14 A

17Q First examination report despatched

Effective date: 20030627

RBV Designated contracting states (corrected)

Designated state(s): DE FR GB IT

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080202